TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10091293
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (5000 U anti-Xa; Fragmin P forte) s.c.
Study: 10091293
Drug: Dose-adjusted coumarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted coumarin (Marcumar) p.o.
Study: 7471600
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg, 100 mg, 200 mg
Study: 7471600
Drug: Sotalol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 50 mg, 100 mg, 200 mg
Study: 7471600
Drug: Metoprolol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 400 mg
Study: 7471600
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg, 100 mg, 200 mg
Study: 27888578
Drug: UltraBLOX™ radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: UltraBLOX™ radiation attenuating hand cream
Study: 24119605
Drug: Triamcinolone (TA)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone (TA) 20 mg-soaked bioabsorbable dressing
Study: 19634512
Drug: Iron(III) hydroxide
Normalized name: Iron(III) hydroxide sucrose complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III) hydroxide polymaltose complex (IPC, Maltofer) containing 100 mg of elemental iron, 6 days a week for 8 months
Study: 11133598
Drug: DCLHb (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (1 g/kg)
Study: 11133598
Drug: DCLHb (936
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (936 +/- 276 mg/kg)
Study: 9926153
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose allergen exposure (individualised to 25% of the total dose causing immediate and late response)
Study: 9926153
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose allergen exposure
Study: 23105144
Drug: 180 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg/week Pegylated interferon alfa-2a
Study: 23105144
Drug: 90 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg/week Pegylated interferon alfa-2a
Study: 23105144
Drug: Sustained viral
Normalized name: Sustain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained viral load <400 copies/mL
Study: 21320217
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to selected music from the evening before surgery to the second day after surgery)
Study: 18181909
Drug: RELIANCE G
Approvals — FDA: no, EMA: no, PMDA: no
Description: RELIANCE G leads
Study: 16644332
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg BID x 4 doses plus hydration
Study: 16644332
Drug: Hydration alone
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration alone (combined oral and rapid intravenous hydration)
Study: 12804346
Drug: Antiretroviral agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral agent prescription
Study: 10644538
Drug: Glucose (1
Normalized name: Fludeoxyglucose (18F)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (1 g/kg body mass)
Study: 10644538
Drug: Sucrose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (1 g/kg body mass)
Study: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 12.5 mg/m2/week x 3
Study: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 10 mg/m2/week x 3
Study: 8888809
Drug: Daunomycin (DNR)
Normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunomycin (DNR) 45 mg/m2/week x 3
Study: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 12.5 mg/m2
Study: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) 10 mg/m2
Study: 1672229
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with tretinoin
Study: 1672229
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment with etretinate
Study: 6210278
Drug: cis‐DDP (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis‐DDP (3 mg/kg iv day 1) and BLM (15‐20 mg iv continuously day 2‐6)
Study: 6210278
Drug: MTX (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (30 mg/m2 iv day 1 + 6) and VDS (3 mg/m2 iv day 2 + 7)
Study: 6210278
Drug: CR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR and PR achieved by surgery and/or x‐ray therapy
Study: 28207840
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation for 20 min twice a day and 19 g of lupin protein supplementation
Study: 24428805
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose multiple micronutrient supplementation
Study: 22942294
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg plus clopidogrel 75 mg
Study: 20620518
Drug: Initial arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial arterial revascularization (IAR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Study: 20620518
Drug: Initial portal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial portal revascularization (IPR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Study: 17463219
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) administered 0 hours relative to pramlintide (120 microg)
Study: 17463219
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) administered +1 hours relative to pramlintide (120 microg)
Study: 17463219
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) administered +2 hours relative to pramlintide (120 microg)
Study: 17463219
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) administered -2 hours relative to pramlintide (120 microg)
Study: 17463219
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) administered -1 hours relative to pramlintide (120 microg)
Study: 11521914
Drug: Expedient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedient and appropriate early treatment of fractures
Study: 2465076
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) with low-dose leucovorin (20 mg/m2) intravenously for 5 days
Study: 2465076
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) with high-dose leucovorin (200 mg/m2) intravenously for 5 days
Study: 2465076
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) alone (500 mg/m2 for 5 days)
Study: 2465076
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) with leucovorin (both doses)
Study: 9954
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg and 500 mg)
Study: 30387193
Drug: 12-hour overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour overnight abstinence from snus (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Study: 30387193
Drug: Satiety condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satiety condition (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Study: 28590567
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (<50 nmol/L) in late pregnancy
Study: 16861094
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg PO QD
Study: 16861094
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg PO QD
Study: 9156268
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions (DLI) with a large dose of donor lymphocytes (≥ 1 x 10(8)/kg) in group A (n = 8)
Study: 9156268
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions (DLI) with escalating doses of cells (2 x 10(5) up to 2 x 10(8)/kg) in group B (n = 10)
Study: 9156268
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (DLI with escalating doses)
Study: 31736428
Drug: Active supplement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supplement containing Bacopa monniera, Panax quinquefolius ginseng, and whole coffee fruit extract
Study: 30241504
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (NaNO2) infusion at 240 μg/kg/hour for 2 hours
Study: 30241504
Drug: Allopurinol 150
Normalized name: allopurinol 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 150 mg twice daily (TD)
Study: 30241504
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg TD
Study: 30241504
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg TD
Study: 17640489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone as free base with 20 mg omeprazole twice daily
Study: 17640489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone as maleate salt with 20 mg omeprazole twice daily
Study: 17640489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone as free base alone
Study: 17640489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone as maleate salt alone
Study: 17640489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone as free base with omeprazole
Study: 15915352
Drug: Probenecid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (500 mg, twice daily for 10 days)
Study: 11914204
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dose of levofloxacin by mouth preoperatively
Study: 2816479
Drug: Estrogen monotherapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen monotherapy (n = 20)
Study: 2816479
Drug: Continuously combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously combined estrogen/progestogen therapy (n = 20)
Study: 2816479
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for estrogen monotherapy (n = 25)
Study: 2816479
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for continuously combined estrogen/progestogen therapy (n = 23)
Study: 2816479
Drug: Post-treatment (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (3 months after hormone withdrawal)
Study: 26591395
Drug: Switch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch therapy (SWT) - switching from IV to oral antibiotics within 24 hours after clinical improvement
Study: 26591395
Drug: Switch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch therapy (SWT)
Study: 24219860
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 molecule)
Study: 22808810
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for 3 days
Study: 22808810
Drug: Cut-off value
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cut-off value of 800 ml for RU
Study: 16786236
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin 80 mg/day)
Study: 16786236
Drug: Moderate statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate statin therapy (pravastatin 40 mg/day)
Study: 16786236
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with LDL < 70 mg/dL
Study: 16786236
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CRP < 2 mg/L
Study: 16786236
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with LDL < 70 mg/dL and CRP < 2 mg/L
Study: 15383180
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients)
Study: 15383180
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of latanoprost 0.005%/timolol 0.5% once daily (LT group: 22 patients)
Study: 12539556
Drug: Xiaokuiling prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaokuiling prescription (XKL)
Study: 9397242
Drug: OPC‐21268 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐21268 (100 mg)
Study: 2822298
Drug: Methoxamine (alpha‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (alpha‐1 adrenoceptor agonist)
Study: 2822298
Drug: Thymoxamine (alpha‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine (alpha‐1 adrenoceptor antagonist)
Study: 22395731
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (levodopa)
Study: 19732095
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg)
Study: 7839475
Drug: Inhaled racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled racemic epinephrine
Study: 12499338
Drug: Basic meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic meal with 50 g pork
Study: 12499338
Drug: Basic meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic meal with 75 g pork
Study: 12499338
Drug: Basic meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic meal with 25 g pork
Study: 11096386
Drug: Epidermal cooling
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal cooling with IPL treatment
Study: 11096386
Drug: Non-cooled IPL
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cooled IPL treatment
Study: 11096386
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment with cooling
Study: 8558209
Drug: G‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 5 micrograms/kg on days 1 to 12 and GM‐CSF at 0.5, 1, or 5 micrograms/kg on days 7 to 12
Study: 8558209
Drug: GM‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 5 micrograms/kg on days 1 to 12 and G‐CSF 5 micrograms/kg on days 7 to 12
Study: 8558209
Drug: G‐CSF added
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF added to patients already receiving GM‐CSF (cohort 4)
Study: 8558209
Drug: GM‐CSF added
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF added to patients already receiving G‐CSF
Study: 31030870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neutral WSAP task or treatment as usual)
Study: 22866291
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 mm dental implants with a novel nanostructured calcium‐incorporated titanium surface
Study: 22866291
Drug: at least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least 5 × 10 mm‐long implants in augmented bone
Study: 19682360
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (MMT)
Study: 30951166
Drug: PrabotulinumtoxinA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Study: 30951166
Drug: OnabotulinumtoxinA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Study: 27244762
Drug: GnRH‐a (Triptorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 1-2 of the cycle (Group A)
Study: 27244762
Drug: GnRH‐a (Triptorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 20-22 of the previous cycle (Group B)
Study: 27244762
Drug: GnRH‐a (Triptorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections (both groups)
Study: 17610534
Drug: Atomoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40 mg qd for 3 days, then 80 mg qd for 7 days)
Study: 10448545
Drug: Lysine acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylic acid (L-ASA) 1.8 g i.v. (1 g acetylsalicylic acid)
Study: 30632837
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus chemotherapy (G + chemo)
Study: 30632837
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus chemotherapy (R + chemo)
Study: 22707132
Drug: Levofloxacin (LVFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LVFX) 250 mg orally
Study: 19166694
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1,500 mg/day) plus placebo
Study: 19166694
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1,500 mg/day) plus gemfibrozil (1,200 mg/day)
Study: 17151802
Drug: Omeprazole (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (high-dose intravenous proton pump inhibitor)
Study: 17151802
Drug: Omeprazole (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (high-dose intravenous proton pump inhibitor) + Misoprostol (600 microg/day)
Study: 15057738
Drug: MRA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA (8 mg/kg biweekly)
Study: 11442185
Drug: Topical verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical verapamil (0.25%)
Study: 9758438
Drug: Iodine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine (0.5 mg/day)
Study: 9758438
Drug: Levo-thyroxine (T4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-thyroxine (T4) (0.125 mg/day)
Study: 3044833
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus Poly(A).Poly(U)
Study: 27878630
Drug: cMyBP‐C plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMyBP‐C plasma levels measured at admission (122.44 ± 41.01 ng/ml)
Study: 27878630
Drug: cMyBP‐C plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMyBP‐C plasma levels measured after treatment (71.38 ± 49.68 ng/ml)
Study: 27878630
Drug: cMyBP‐C plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMyBP‐C plasma levels at admission (cutoff point of 45 ng/ml)
Study: 27878630
Drug: cMyBP‐C plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMyBP‐C plasma levels at admission (cutoff point of 152 ng/ml)
Study: 26142168
Drug: Combined physical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physical and occupational therapy (Group B, n=30)
Study: 26142168
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only (Group A, n=31)
Study: 11015511
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral iron supplementation (EI) of 2 to 6 mg/kg/day
Study: 6354151
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) high‐dosage cyclophosphamide
Study: 26932324
Drug: Cessation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation treatment
Study: 15461066
Drug: Stage IIa
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IIa PAD treatment
Study: 15461066
Drug: Stage IIb
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IIb PAD treatment
Study: 15461066
Drug: Stage III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage III PAD treatment
Study: 15461066
Drug: Stage IV
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IV PAD treatment
Study: 27740724
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment costs
Study: 2606594
Drug: MaxEPA fish
Normalized name: MAXEPA FISH OIL CONCENTRATE CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxEPA fish oil diet (6 g daily for 6 weeks)
Study: 27176943
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity on Prescription (PaP) with conventional treatment
Study: 20644583
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT) with effluent flow rates >25 ml/kg per hour
Study: 18540016
Drug: Micro-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-implants